The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:724-725 February 17, 2005 Number 7
NextNext

Lymphoma-Infiltrating Immune Cells

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Dave, S. S.
-PubMed Citation
To the Editor: Dave et al. (Nov. 18 issue)1 report their findings concerning the molecular features of tumor-infiltrating immune cells in follicular lymphoma. This low-grade lymphoma includes heterogeneous subtypes that require different treatment strategies. Several important variables for predicting the prognosis of follicular lymphoma are lacking in this report. First, although the t(14;18)(q32;q21) mutation is the cytogenetic hallmark of follicular lymphoma, follicular lymphoma without this translocation exists and has distinct clinical features.2 Second, grades 1, 2, and 3a follicular lymphomas constitute a spectrum of indolent lymphoma, whereas grade 3b is similar to diffuse large lymphoma.3 Third, the presence of large, . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.